Key stats
- Market cap
- 11.5B
- Open
- —
- Day range
- —
- 52-week range
- $126.40 – $354.88
- Volume
- 2.00M
- Avg volume
- 1.39M
Q3 FY26Beat
Expected$1.62
Actual$1.99
PODD
Insulet Corporation$166.09+$11.23+7.25%Price as of Nov 4, 2026, 5:30 PM ET
Earnings
Q2 FY26
Actual$1.37
Q1 FY26
Actual$1.30
Q4 FY25
Actual$1.41
About
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
- Employees
- 5,400
- Headquarters
- Acton, MA